Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels. We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-β1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion. Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors —inexpensive drugs with decades of safe use — could be rapidly repurposed as cancer therapeutics. Hyaluronan is a component of the tumour extracellular matrix. Here, Chauhan et al. show that hyaluronan increases blood pressure in collagen-rich tumours by compressing vessel walls, and that reducing the level of hyaluranon with an angiotensin II inhibitor increases blood flow and drug penetrance in tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, antiangiogenic drugs have a synergistic antitumor effect in combination with radiotherapy and chemotherapy in clinical practice.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [260]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased mechanical stress can collapse blood vessels, leading to hypoxia, thereby promoting more aggressive cancer phenotypes, and reducing drug delivery89,100–105.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We have also shown that widely prescribed ARBs can normalize the stroma and decompress blood vessels, thereby improving the outcome of chemotherapy94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
In the citing paper
“results from our laboratory have shown that the elevated levels of extracellular matrix molecules, including collagen I and hyaluronan, in such tumours can compress blood vessels, impairing their function and resulting in hypoxia94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“Hyaluronan has been proposed to be the primary matrix molecule responsible for vessel compression 12 , but its exact mechanism remains unclear.”
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · cited 1×
“This might be attributed to resistance induced by the immune microenvironment 39 .”
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628 · cited 2×
“We then studied oxygenation using phosphorescence quenching microscopy 35 .”
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248 · cited 2×
“…data notwithstanding, it should be noted that antiangiogenic therapy with bevacizumab has failed to prolong survival in desmoplastic tumours such as breast and pancreatic cancer 3 , casting doubt on a possible antiangiogenic mechanism for the benefits observed with angiotensin inhibitors.”
Self-citationChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943 · cited 6×
“Both hyaluronan and collagen fibres contribute to solid stress in tumours: hyaluronan does so by resisting compression, whereas collagen does so by resisting tension and confining the local microenvironment 5 .”
InfluentialSelf-citationSolid stress inhibits the growth of multicellular tumor spheroids
Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J., & Jain, R. K. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-778 · Cited by 859 · cited 1×
“Solid stress (pressure from solid tissue components) accumulates in tumours as cancer and stromal cells proliferate in a confined microenvironment created by crosslinked matrix molecules 4–6 .”
Self-citationEffects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor
Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. M., & lnagami, T. (1995) · Nature · doi:10.1038/377748a0 · Cited by 858
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857 · cited 2×
“The matrix stores and transmits this stress throughout the tumour 7 , collapsing blood vessels to limit perfusion 8,9 .”
Self-citation
Cited by
Items 601–700 of 1,000
Ware, M. J., Curtis, L. T., Wu, M., Ho, J. C., Corr, S. J., Curley, S. A., Godin, B., & Frieboes, H. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-03040-0 · Cited by 18
Xiao, N., Liu, J., Liao, L., Sun, J., Jin, W., & Shu, X. (2018) · Ultrasound Quarterly · doi:10.1097/ruq.0000000000000381 · Cited by 20
Hasselluhn, M. C., Klein, L., Patzak, M. S., Buchholz, S. M., Ströbel, P., Ellenrieder, V., Maisonneuve, P., & Neeße, A. (2019) · Cells · doi:10.3390/cells9010058 · Cited by 19
Understanding the In Vivo Fate of Advanced Materials by Imaging
Li, R., Ng, T. S. C., Garlin, M. A., Weissleder, R., & Miller, M. A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910369 · Cited by 20
Therapeutic agents for targeting desmoplasia: current status and emerging trends
Nandi, T., Pradyuth, S. K., Singh, A. K., Chitkara, D., & Mittal, A. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.008 · Cited by 21
Chatterjee, K., Atay, N., Abler, D., Bhargava, S., Sahoo, P., Rockne, R. C., & Munson, J. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020212 · Cited by 20
Zeng, Z., Ma, C., Chen, K., Jiang, M., Vasu, R., Liu, R., Zhao, Y., & Zhang, H. (2021) · Cells · doi:10.3390/cells10112988 · Cited by 18
“As a result, the epithelial-to-mesenchymal transition (EMT) and tumor microenvironment (TME) are changed, interfering with cancer growth and progression [10,11].”
BackgroundScodeller, P. (2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000178 · Cited by 19
“Other ECM components, namely, Collagen I and Laminin I are overexpressed in certain types of cancers like breast tumors, as evidenced by immunohistochemistry [58,59].”
BackgroundBiomaterials for Abrogating Metastasis: Bridging the Gap between Basic and Translational Research
Conde, J., Shomron, N., & Artzi, N. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600414 · Cited by 20
Martin, J. D., Fukumura, D., Duda, D. G., Boucher, Y., & Jain, R. K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031195 · Cited by 18
Self-citationLuo, L., Wang, X., Liao, Y.-P., Xu, X., Chang, C. H., & Nel, A. E. (2024) · Nano Today · doi:10.1016/j.nantod.2023.102058 · Cited by 16
Voutouri, C., Englezos, D., Zamboglou, C., Strouthos, I., Papanastasiou, G., & Stylianopoulos, T. (2024) · Communications Medicine · doi:10.1038/s43856-024-00634-4 · Cited by 19
Self-citationWelter, M., & Rieger, H. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-42023-3_3 · Cited by 20
The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective
Batista, S., Gregório, A. C., Otake, A. H., Couto, N., & Costa‐Silva, B. (2019) · Journal of Oncology · doi:10.1155/2019/6240505 · Cited by 17
“Losartan + F-NOX PDAC TGF-beta1 Fibrosis [230] II NCT03563248∗ IPI-926 + gemcitabine PDAC SMO Hedgehog pathway inhibition II NCT01130142 PEGPH20+ gemcitabine + nabpaclitaxel PDAC Hyaluronan Desmoplasia [232, 233] III NCT02715804 ∗”
BackgroundGomi, M., Sakurai, Y., Okada, T., Miura, N., Tanaka, H., & Akita, H. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.014 · Cited by 18
Panza, S., Malivindi, R., Caruso, A., Russo, U., Giordano, F., Győrffy, B., Gelsomino, L., Amicis, F. D., Barone, I., Conforti, F. L., et al. (2021) · Cancers · doi:10.3390/cancers13184555 · Cited by 18
“Based on our present findings, we formulated the idea that the inhibitory effect of LOS on the EMT process in GBM cells may also be indirectly reinforced by its inhibitory action on local estrogen production [45,46].”
BackgroundFeng, X., Liu, H., Pan, J. M., Xiong, Y., Zhu, X., Yan, X., Duan, Y., & Huang, Y. P. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00753 · Cited by 17
Self-citationLi, P.-C., Huang, R., Yang, Y.-C., Hsieh, K., & Yang, Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-09513-4 · Cited by 19
The Role of Hitchhiking in Cancer Therapeutics—A Review
Padmakumar, A., Koyande, N. P., & Rengan, A. K. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200042 · Cited by 20
Marine-Inspired Drugs and Biomaterials in the Perspective of Pancreatic Cancer Therapies
Fernandes, A. M., Oliveira, C., Reis, R. L., Martins, A. M., & Silva, T. H. (2022) · Marine Drugs · doi:10.3390/md20110689 · Cited by 23
Colard‐Thomas, J., Thomas, Q. D., & Viala, M. (2023) · Cancers · doi:10.3390/cancers15082276 · Cited by 22
“Moreover, RAAS inhibitors’ action on the tumor microenvironment involves blood vessel decompression and therefore better tumor perfusion, allowing for hypoxia alleviation and better drug delivery [126].”
BackgroundFighting the force: Potential of homeobox genes for tumor microenvironment regulation
Northcott, J. M., Northey, J. J., Barnes, J. M., & Weaver, V. M. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.03.004 · Cited by 17
“This data complements the findings that blood and lymphatic vessels within the tumor core are often compressed or collapsed due to tumor solid stress, whereas vessels in the periphery are leaky due to abnormal interstitial fluid pressure [21].”
He, J., Xue, W., & Li, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s560983 · Cited by 16
Ramaswamy, A., BHARGAVA, P. G., Gota, V. S., Srinivas, S., Sultana, N., Mandavkar, S., Jadhav, P., Gandhi, K., Mer, N., Khan, N., et al. (2025) · Cancer · doi:10.1002/cncr.35945 · Cited by 16
Li, M., Wang, C., Liu, H., Xu, Z., & Liu, Y. (2025) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/14703203251367136 · Cited by 19
“178,179 In hypertensive rats, miR-21 exhibits elevated expression, which reduces the levels of anti-apoptotic Bcl-2 and triggers apoptosis.”
Self-citationTumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas
Charalambous, A., Mpekris, F., Panagi, M., Voutouri, C., Michael, C., Gabizón, A., & Stylianopoulos, T. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0772 · Cited by 17
Self-citationA biomimetic dual-targeting nanomedicine for pancreatic cancer therapy
Zhou, G., Zhang, Y., Cai, Z., Yao, H., Liu, M., Jiang, C., & Cheng, Z. (2025) · Journal of Materials Chemistry B · doi:10.1039/d4tb02206h · Cited by 17
Hosseinimehr, S. J. (2014) · Future Oncology · doi:10.2217/fon.14.177 · Cited by 16
Hofmann, C. L., O’Sullivan, M. C., Detappe, A., Yu, Y., Yang, X., Qi, W., Landon, C. D., Therien, M. J., Dewhirst, M. W., Ghoroghchian, P. P., et al. (2017) · Nanoscale · doi:10.1039/c7nr02363d · Cited by 16
“The images revealed that the majority of the PZn3-loaded PEG-b-TCL-based micelles accumulated within the liver and spleen of each animal, which are known organs for nanoparticle accumulation (10, 30).”
Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma
Jain, R., Skelton, W. P., Pond, G. R., Naqvi, S. M. H., Kim, Y., Curran, C. R., Freeman, D. A., Nuzzo, P. V., Alaiwi, S. A., Nassar, A. H., et al. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.04.002 · Cited by 19
Self-citationMartin, J. D., Lanning, R. M., Chauhan, V. P., Martin, M. R., Mousa, A. S., Kamoun, W. S., Han, H., Lee, H., Stylianopoulos, T., Bawendi, M. G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0486 · Cited by 17
Self-citationKawahata, H., Sotobayashi, D., Aoki, M., Shimizu, H., Nakagami, H., Ogihara, T., & Morishita, R. (2015) · Hypertension Research · doi:10.1038/hr.2015.18 · Cited by 17
Finite Element Modeling of Avascular Tumor Growth Using a Stress-Driven Model
Iranmanesh, F., & Nazari, M. A. (2017) · Journal of Biomechanical Engineering · doi:10.1115/1.4037038 · Cited by 17
Yin, C., Wang, S., Ren, Q., Shen, X., Chen, X., Liu, Y., & Liu, S. (2019) · 中国科学通报:英文版 · doi:10.1016/j.scib.2019.04.017 · Cited by 16
Strategies of targeting pathological stroma for enhanced antitumor therapies
Zhu, Y., Yu, F., Tan, Y., Yuan, H., & Hu, F. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104401 · Cited by 16
The Biophysics of Cancer: Emerging Insights from Micro‐ and Nanoscale Tools
Beshay, P. E., Cortes-Medina, M. G., Menyhert, M. M., & Song, J. W. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100056 · Cited by 17
Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment
Arnold, F., Vecchio, A. D., Hussain, Z., & Sherman, M. H. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00905-9 · Cited by 17
Pirfenidone alleviates fibrosis by acting on tumour–stroma interplay in pancreatic cancer
Lei, Y., Xu, J., Xiao, M., Wu, D., Xu, H., Yang, J., Mao, X., Pan, H., Yu, X., & Shi, S. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02631-9 · Cited by 15
Kalupahana, N. S., & Moustaïd‐Moussa, N. (2024) · Acta Physiologica · doi:10.1111/apha.14164 · Cited by 15
Injectable Hydrogels for Intratumoral Administration Against Breast Cancer
Bagheri, E., Ramezani, M., Mohammadi, M., & Alibolandi, M. (2024) · Journal of Polymers and the Environment · doi:10.1007/s10924-024-03344-z · Cited by 15
“However, the growth rate of tumor cells was not reduced by the administration of losartan alone and thus additional chemotherapy treatment was essential [89].”
Zhou, L., Zhang, W., Hu, X., Wang, D., & Tang, D. (2024) · Clinical Medicine Insights Oncology · doi:10.1177/11795549241287058 · Cited by 17
“81 radiotherapy has not yet been discovered, and whether there is an association between them is also a question worth exploring.”
BackgroundNeophytou, C., Charalambous, A., Voutouri, C., Angeli, S., Panagi, M., Stylianopoulos, T., & Mpekris, F. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113722 · Cited by 16
Self-citationRoix, J. J., Harrison, S. D., Rainbolt, E. A., Meshaw, K. R., McMurry, A. S., Cheung, P., & Saha, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101708 · Cited by 15
“The authors propose a complex mode-of-action involving vasculogenesis in complex tumor stroma tissue [19].”
BackgroundMeasuring Vascular Permeability In Vivo
Meijer, E. F. J., Baish, J. W., Padera, T. P., & Fukumura, D. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3801-8_6 · Cited by 17
Meng, T., Liu, J., Wen, L., Yuan, M., Cheng, B., Hu, Y., Zhu, Y., Liu, X., Yuan, H., & Hu, F. (2016) · Oncotarget · doi:10.18632/oncotarget.12159 · Cited by 15
Cazacu, I. M., Săftoiu, A., Bhutani, M., Itoi, T., Arcidiacono, P. G., Bories, E., Constantin, A. L., Coronel, E. S., Dietrich, C. F., Duda, D. G., et al. (2019) · Endoscopic Ultrasound · doi:10.4103/eus.eus_16_19 · Cited by 15
“Chauhan et al.[15] demonstrated that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production.”
BackgroundMethodPhan, C. U., Zheng, Z., Wang, J., Wang, Q., Hu, X.-R., Tang, G., & Bai, H. (2019) · Biomaterials Science · doi:10.1039/c9bm01190k · Cited by 15
Stellate Cells in the Tumor Microenvironment
Roife, D., Sarcar, B., & Fleming, J. B. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-44518-8_6 · Cited by 15
Saha, A., & Anirvan, P. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1099 · Cited by 16
“Upon activation, CAF also increases the synthesis of collagen-1, promoting fibrosis that induces hypoxia by compressing the blood supply [32], while hypoxia itself may lead to expression of immune-inhibitory molecules like programmed death ligand 1, reduction in the potential of the tumour killing cells and reprogramm…”
BackgroundClinical applicability of renin-angiotensin system inhibitors in cancer treatment.
Jiang, H., Tai, Z., Chen, Z., Zhu, Q., & Bao, L. (2021) · American Journal of Cancer Research · Cited by 25
Surapaneni, S. K., Nottingham, E., Mondal, A., Patel, N., Arthur, P., Gebeyehu, A., Kalvala, A. K., Rishi, A. K., & Singh, M. S. (2021) · Anticancer Research · doi:10.21873/anticanres.15226 · Cited by 15
Durymanov, M. O., Yarutkin, A. V., Bagrov, D. V., Klinov, D. V., Kedrov, A. V., Chemeris, N. K., Rosenkranz, A. A., & Sobolev, A. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.011 · Cited by 15
“Because both collagen I and hyaluronan levels may vary in different tumors, LS is able to promote decompression and reperfusion of vessels differently in different tumor models [17].”
BackgroundMethodComplex Effects of Tumor Microenvironment on the Tumor Disposition of carrier-mediated Agents
Lucas, A. T., Price, L., Schorzman, A. N., & Zamboni, W. C. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0101 · Cited by 15
Oliveira, R. G. S., Orsolin, P. C., & Nepomuceno, J. C. (2016) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.07.003 · Cited by 15
Cai, X., Wang, Z., Xu, Y., Yang, G., Zhang, R.-Y., & Wang, Y. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00842-0 · Cited by 14
Repurposing Drugs in Small Animal Oncology
Giuliano, A., Horta, R. D. S., Vieira, R. A. D. M., Hume, K. R., & Dobson, J. M. (2022) · Animals · doi:10.3390/ani13010139 · Cited by 15
“Indeed, in a small phase II study in humans with advanced pancreatic cancer, the addition of losartan to standard neoadjuvant chemotherapy has shown some promising results [49,51].”
BackgroundLuo, F., Li, M., Chen, Y., Song, S., Yu, H., Zhang, P., Xiao, C., Lv, G., & Chen, X. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122476 · Cited by 16
Mathematical model of oxygen, nutrient, and drug transport in tuberculosis granulomas
Datta, M., Kennedy, M., Siri, S., Via, L. E., Baish, J. W., Xu, L., Dartois, V. A., Barry, C. E., & Jain, R. K. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011847 · Cited by 16
Self-citationThe tumor-associated fibrotic reactions in microenvironment aggravate glioma chemoresistance
Xu, J., Zhang, J., Chen, W., & Ni, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1388700 · Cited by 17
“Currently, anti fi brosis drugs such as tranilast, losartan, and pirfenidone, have been used to improve chemotherapy in solid tumors (63, 70, 71), while it warrants subsequent research to con fi rm their ef fi cacy in glioma.”
BackgroundChen, W., Zhang, Z., Han, Y., Li, X., Liu, C., Sun, Y., Ren, Y., & Guan, X. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123104 · Cited by 14
Olsson, P. O., Gustafsson, R., Zandt, R. I. ‘., Friman, T., Maccarana, M., Tykesson, E., Oldberg, Å., Rubin, K., & Kalamajski, S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0026 · Cited by 14
“Available data have indeed shown that modulation of the ECM-composition, notably the major ECM-constituents collagen and/or glycosaminoglycans, influence solid stress in carcinoma and thereby compression of blood vessels (13, 14, 46).”
BackgroundJohansen, M. D., Urup, T. H., Holst, C. B., Christensen, I. J., Grunnet, K., Lassen, U., Friis, S., & Poulsen, H. S. (2018) · Cancer Investigation · doi:10.1080/07357907.2018.1544639 · Cited by 14
“17 Yes 17(65) 98(51) – No 9(35) 94(49) – Toxicity, hypertension, n (%) – – – Grade 1 or 2 8(31) 19(10) .”
BackgroundDynamic control of tumor vasculature improves antitumor responses in a regional model of melanoma
Gabriel, E. M., Kim, M., Fisher, D. T., Powers, C. A., Attwood, K. M., Bagaria, S. P., Knutson, K. L., & Skitzki, J. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-70233-5 · Cited by 15
Gabriel, E. M., Kim, M., Fisher, D. T., Mangum, C., Attwood, K. M., Ji, W., Mukhopadhyay, D., Bagaria, S. P., Robertson, M. W., Dinh, T. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84430-3 · Cited by 14
Aggrecan: Approaches to Study Biophysical and Biomechanical Properties
Nia, H. T., Christine Ortiz, B., & Grodzinsky, A. J. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1714-3_20 · Cited by 14
Jain, R. K., Martin, J. D., Chauhan, V. P., & Duda, D. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00008-6 · Cited by 16
Self-citationStone, S., McPherson, J. P., Kulkarni, R. P., & Young, A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00890-z · Cited by 15
“…system inhibition also reduces solid stress, a mechanical force compressing tumour blood vessels and leading to hypoxia and acidity in the TME which, in turn, may promote T reg cell activity, increased expression of PDL1 and suppressed cytotoxic lymphocyte activity 182,183 .”
Alteration of mechanical stresses in the murine brain by age and hemorrhagic stroke
Zheng, S., Banerji, R., LeBourdais, R., Zhang, S., DuBois, E. M., O’Shea, T. M., & Nia, H. T. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae141 · Cited by 14
“During tumor growth, residual solid stresses were shown to be a key contributor in tumor progression (13, 14), immune evasion (15 ), and treatment resistance by directly compressing the blood and lymphatic vessels (12, 16, 17) or directly compressing the cancer cells (18, 19).”
BackgroundBurchard, P. R., Ruffolo, L. I., Ullman, N. A., Dale, B. S., Dave, Y. A., Chu, B. K. H., Ye, J., Georger, M. A., Jewell, R., Miller, C., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000502 · Cited by 15
“[28,29] Therefore, we investigated whether pan-LOX inhibition with PXS-5505 could reverse intra-tumoral compression and enhance vascular perfusion in iCCA tumors.”
BackgroundResultKashkooli, F. M., Mirala, F., Tehrani, M. H. H., Alirahimi, M., Souri, M., Golzaryan, A., Kar, S., & Soltani, M. (2025) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.70000 · Cited by 19
Rathi, P., Chowdhury, S., & Siril, P. F. (2025) · Small · doi:10.1002/smll.202505835 · Cited by 17
More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer
Seufferlein, T. T. W., Ducreux, M. P., Hidalgo, M. M., Prager, G. W., & Cutsem, E. V. (2018) · European Oncology & Haematology · doi:10.17925/eoh.2018.14.1.40 · Cited by 14
Meijer, E. F. J., Bouta, E. M., Mendonca, C., Skolny, M. N., Salama, L., Taghian, A. G., & Padera, T. P. (2020) · Clinical Research and Trials · doi:10.15761/crt.1000293 · Cited by 13
“Angiotensin converting enzyme (ACE) inhibitors have been shown to have similar, but lesser, anti-fibrotic effects [26].”
BackgroundCai, T., Jiang, J., Yao, W., Hu, Y., Kong, S., Fan, Q., Yan, X., Li, F., & Shi, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114015 · Cited by 14
Chiang, C., Wang, S.-S., Chang, Y., Chiang, C., Chen, C., Chen, Y.-J., See, X. Y., Peng, C.-Y., Hsia, Y., Chiang, C., et al. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.02.014 · Cited by 13
The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis
Gregory, G. E., Islim, A. I., Hannan, C. J., Jones, A. P., Hammerbeck-Ward, C. L., Rutherford, S. A., Freeman, S. R. M., Lloyd, S., Kalamarides, M., Smith, M. J., et al. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac127 · Cited by 14
Mascheroni, P., Penta, R., & Merodio, J. (2023) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-023-01742-1 · Cited by 13
“7, where a reduction of vascular density correlates to higher-pressure differences between compartments.”
BackgroundInterstitial Fluid in Gynecologic Tumors and Its Possible Application in the Clinical Practice
Ura, B., Lorenzo, G. D., Romano, F., Monasta, L., Mirenda, G., Scrimin, F., & Ricci, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124018 · Cited by 14
On the Impact of Chemo-Mechanically Induced Phenotypic Transitions in Gliomas
Mascheroni, P., Alfonso, J. C. L., Kalli, M., Stylianopoulos, T., Meyer‐Hermann, M., & Hatzikirou, H. (2019) · Cancers · doi:10.3390/cancers11050716 · Cited by 14
Self-citationLamouline, A., Bersini, S., & Moretti, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135401 · Cited by 15
“This effect can be reduced by a blood-pressure medication, Losartan, that decreases both the amount of collagen and hyaluronan causing vessel compression, and MAF activation (41).”
BackgroundZhang, X., Zhao, Y., Teng, Z., Sun, T., Tao, J., Wu, J., Wang, Y., Qiu, F., & Wang, F. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s467968 · Cited by 12
“22 A retrospective study showed that the angiotensin I-converting enzyme inhibitors (ACEIs)/ ARBs in combination with gemcitabine may improve clinical outcomes in patients with advanced pancreatic cancer.”
BackgroundYang, J., Chen, M., Li, R., Sun, Y., Ye, P., Fang, K., Wang, C., Shi, S., & Dong, C. (2025) · Nanoscale · doi:10.1039/d4nr03054k · Cited by 12
Zaheer, J., Shanmugiah, J., Kim, S., Kim, H., & Kim, J. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-97983-4 · Cited by 15
Dwairy, M., Yehya, A., Mohammad, F. M., & Alzoubi, H. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328196 · Cited by 14
“Our findings are in line with other studies that noted improved tumor oxygenation after alleviating intratumoral mechanical stress [17,32].”
InfluentialMeng, Y., Zhou, L., Xia, Y., Jia, C., & Huang, L. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118703 · Cited by 17
Heterogeneity in Pancreatic Cancer Fibroblasts—TGFβ as a Master Regulator?
Watt, D. M., & Morton, J. P. (2021) · Cancers · doi:10.3390/cancers13194984 · Cited by 14
Nimma, R., Kalvala, A. K., Patel, N., Surapaneni, S. K., Sun, L. J., Singh, R. K., Nottingham, E., Bagde, A., Kommineni, N., Arthur, P., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061156 · Cited by 13
Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer
Gautam, S. K., Dalal, V., Sajja, B. R., Gupta, S., Gulati, M., Dwivedi, N. V., Aithal, A., Cox, J. L., Rachagani, S., Liu, Y., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215801 · Cited by 14
Zhao, J., Dong, Y., Zhang, Y., Wang, J., & Wang, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114585 · Cited by 12
Tang, L., Duan, R., Zhong, Y.-J., Firestone, R. A., Hong, Y.-P., Li, J.-G., Xin, Y., Wu, H., & Li, Y. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-44 · Cited by 12
“Drawbacks to the use of MAbs have been that (1) the limited diffusion of MAbs due to their large macromolecules into solid tumors could compromise their potency; (2) heterogeneous antigen expression in large tumors will evidently lead a portion of tumor cells in the solid tumor unresponsive to MAbs; (3) the tumor Ag t…”
Renin–Angiotensin System in the Tumor Microenvironment
Nakamura, K., Okuyama, R., & Kawakami, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50224-9_7 · Cited by 12
Pinheiro, L. C. P., Perdomo‐Pantoja, A., Casaos, J., Huq, S., Paldor, I., Vigilar, V., Mangraviti, A., Wang, Y., Witham, T. F., Brem, H., et al. (2021) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2021.106771 · Cited by 12
Uterine perfusion model for analyzing barriers to transport in fibroids
Stirland, D. L., Nichols, J. W., Jarboe, E. A., Adelman, M., Dassel, M., Janat-Amsbury, M.-M., & Bae, Y. H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.006 · Cited by 13
Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors
Lane, R. S., & Lund, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02662 · Cited by 12
“hyaluronan) thus reducing interstitial fluid pressures (134), or reduce ECM deposition and alignment (135) improved immune infiltration and therapeutic response.”
BackgroundMohanty, R. P., Liu, X., Kim, J. Y., Peng, X., Bhandari, S., Leal, J., Arasappan, D., Wylie, D., Dong, T., & Ghosh, D. (2019) · Nanoscale · doi:10.1039/c9nr05783h · Cited by 12
Current Status of Research on Losartan in Tumour Therapy
Wang, H., Yuan, S., & Wang, H. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70985 · Cited by 11
“However, it is crucial to acknowledge that its efficacy as a monotherapy is likely limited, and its success is predominantly envisioned within rational combination strategies [13, 18, 19].”
InfluentialFibrillin-1 Regulates Arteriole Integrity in the Retina
Alonso, F., Li, L., Frémaux, I., Reinhardt, D. P., & Genot, E. M. (2022) · Biomolecules · doi:10.3390/biom12101330 · Cited by 11
Leveraging insights from cancer to improve tuberculosis therapy
Datta, M., Via, L. E., Dartois, V. A., Xu, L., Barry, C. E., & Jain, R. K. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.07.011 · Cited by 12
Self-citationEngelbrecht, E., Kooistra, T., Burg, N. D., Hariri, L. P., Nguyen, T. H., Brazee, P. L., Hla, T., Gochuico, B. R., & Knipe, R. S. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70102 · Cited by 15
Siboro, P. Y., Nguyen, N., Lo, S., Mi, F., Wu, W., Wang, C., Chen, Y., Pan, W., Peng, S., Nguyen, L., et al. (2025) · Advanced Materials · doi:10.1002/adma.202507607 · Cited by 12
Metadata
- Authors
- Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., Popović, Z., Huang, P., Bawendi, M. G., Boucher, Y., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- ORCID
- Venue
- Nature Communications
- Published
- 2013-10-01
- Volume
- 4
- Issue
- 1
- Pages
- 2516-2516
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3806395
- OpenAlex
- W1603491949
- Cited by
- 1,031
- References
- 64
- Citations by year
- 2026: 85 · 2025: 77 · 2024: 86 · 2023: 101 · 2022: 96 · 2021: 128 · 2020: 92 · 2019: 82 · 2018: 66 · 2017: 69 · 2016: 56 · 2015: 54 · 2014: 31 · 2013: 7
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- Lustgarten Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health (1s10rr027070-01, W81XWH, CA080124, CA085140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, T32CA073479, R01CA085140, P01-CA126642, R01-CA11576, P01CA080124, R01CA126642, R01CA098706)
- National Institute of Biomedical Imaging and Bioengineering (P41EB015903)
- National Center for Research Resources (S10-RR027070)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- losartan, hyaluronic acid, tumor stroma, solid stress, collagen, TGF-β1, connective tissue growth factor, endothelin-1, drug delivery, tumor hypoxia, chemotherapy potentiation, breast cancer, pancreatic cancer, drug repurposing
- MeSH terms
- Angiotensins, Animals, Antineoplastic Agents, Collagen, Drug Synergism, Female, Fluorouracil, Humans, Hyaluronic Acid, Mammary Neoplasms, Experimental, Pancreatic Neoplasms, Stress, Mechanical, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Stromal Cells, Endothelin-1, Losartan, Mechanotransduction, Cellular, Receptor, Angiotensin, Type 1, Angiotensin II Type 1 Receptor Blockers, Mice, Transforming Growth Factor beta1, Connective Tissue Growth Factor, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.